Meibangmeihe Biotechnology

Meibangmeihe Biotechnology Co., Ltd.

Meibangmeihe Biotechnology Co., Ltd. (“Meibangmeihe”) is a wholly-owned subsidiary of Hebei MeiBang Engineering & Technology Co., Ltd. It was incorporated on April 11, 2019, and the registered capital is RMB 50 million.

 

Main Business: Biotechnology, biocatalysis technology and related technology research and development, transfer and technical services; Biological enzyme, coenzyme, biological products, health products raw materials, cosmetics raw materials, pharmaceutical intermediates, fine chemicals research and development, production and sales; R & D, production and sales of pharmaceutical and health care products; Import and export of products and technologies, etc.

 

Based on the research and development of green bio-manufacturing technology, the company layouts bio-based materials, large health industry, pharmaceutical intermediates, fine chemicals and other fields. We make full use of the advantages of biotechnology, such as high efficiency, low side effects, mild conditions, low energy consumption, less waste and high safety factor, to provide strong support for the strategic emerging biotechnology industry.

 

 

We have built the synthetic biotechnology R & D center with an area of about 2400 square meters.This center is mainly used in the research and development of upstream experiments,middle-stream fermentation, downstream separation and purification of synthetic biology and biocatalysis, and equipped with corresponding detection and analysis. It can test project process routes, prepare the testing strain and optimize other R & D technology and process paths. Furthermore, it has strong R & D advantages in the fields of biosynthesis and biocatalysis.

 

It has built the pilot-scale test platform, which can meet the requirements of various unit operation of biocatalysis. After the laboratory research, the pilot test research provides the basis for the design and production of industrial production lines, and can be used for external services.

深川股份

Main direction

Biological materials

Biological materials

Mainly nylon materials, especially the research and development and production of nylon 56 bio-based materials.

Biological health

Biological health

Develop raw materials and products with the goal of high-end projects such as biological health and health products, especially for intermediates or health products of anti-aging, cardio cerebrovascular, diabetes and other long-term drugs.

Pharmaceutical intermediates and fine chemicals

Pharmaceutical intermediates and fine chemicals

Targeting at pharmaceutical intermediates and fine chemicals with important status or large scale, we will use biosynthesis and technology to replace the existing chemical route or develop new routes to improve technology and layout the industry.